Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Improved radioimmunodetection of carcinomas with a re-injection of monoclonal antibodies after formation of anti-mouse antibodies.
Curr Pharm Des
May 2023
Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), Grupo GIR USAL: BMD (Bases Moleculares del Desarrollo), University of Salamanca, 37007, Salamanca, Spain.
Scintigraphic imaging was satisfactory in animal experiments, i.e., in the radioimmunodetection with 125J anti-tissue polypeptide antigen monoclonal antibodies and implanted HELA cell carcinomas.
View Article and Find Full Text PDFThe Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Eur Urol Focus
January 2020
Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy.
Context: Preliminary results have demonstrated that prostate-specific membrane antigen (PSMA) is highly expressed on the cell surface of the microvasculature of several solid tumors, including renal cell carcinoma (RCC).
Objective: To assess the role of PSMA positron emission tomography (PET)/computed tomography (CT) in RCC patients and to discuss its possible inclusion in the clinical management of these patients.
Evidence Acquisition: A systematic literature search was performed for studies on PET/CT in patients with RCC up to April 2018.
Radiolabeled F(ab')-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.
Clin Transl Oncol
December 2018
Service de médecine nucléaire, Centre Georges-François Leclerc, 1 rue du professeur Marion, 21000, Dijon, France.
Purpose: This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, In and Lu, respectively.
Methods: We designed F(ab')-fragments of cetuximab radiolabeled with In and Lu. In-F(ab')-cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors.
Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniques.
Urol Oncol
July 2013
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Objective: Prostate specific membrane antigen (PSMA) is primarily expressed in glandular prostatic tissue and is frequently utilized to detect primary or metastatic prostatic adenocarcinoma (CaP). A purported novel application of PSMA detection is the intraoperative real-time identification of CaP using radioimmunoscintigraphy to define the extension of the surgical resection. Considering that PSMA expression has been reported in other tissues, we evaluated its immunoexpression in prostatic neurovascular bundle elements to assess the convenience and safety of the aforementioned procedure.
View Article and Find Full Text PDFImmuno-positron emission tomography in cancer models.
Semin Nucl Med
May 2010
Department of Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA.
Positron emission tomography (PET) is playing an increasingly important role in the diagnosis, staging, and monitoring response to treatment in a variety of cancers. Recent efforts have focused on immuno-PET, which uses antibody-based radiotracers, to image tumors based on expression of tumor-associated antigens. It is postulated that the specificity afforded by antibody targeting should both improve tumor detection and provide phenotypic information related to primary and metastatic lesions that will guide therapy decisions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!